New hope for NF1 patients: targeted drug shrinks inoperable tumors in early trial
NCT ID NCT04590235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The goal is to check the drug's safety and how well it works at shrinking these tumors. Participants take the drug by mouth, and doctors monitor side effects and tumor size using MRI scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Shanghai, 200011, China
-
Research Site
Shanghai, CN-200092, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia
- New stem cell transplant aims to cut dangerous side effects in blood cancer patients